1. Introduction {#sec1}
===============

Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive disease with a 5-year survival rate as low as 6% that has traditionally demonstrated resistance to systemic therapies \[[@bib1]\]. Studies from patients with PDAC have demonstrated that many patients have multifocal, microscopic pancreatic intraepithelial neoplasms (PanINs) surrounding the tumor \[[@bib2], [@bib3], [@bib4], [@bib5]\]. Those PanINs are asymptomatic non-invasive microscopic flat or papillary lesions that arise within small intralobular pancreatic ducts and are classified into three grades: *PanIN-1A* (flat) and *PanIN-1B* (papillary) representing low-grade lesions, *PanIN-2* representing intermediate-grade PanIN, and *PanIN-3* - also referred to as *"carcinoma in situ" -* demonstrating high-grade PanINs.

Resistance to therapies in PDAC has been attributed, in part, to the potential "tumor-protecting" extensive fibrous (desmoplastic) stroma that surrounds malignant cells \[[@bib6]\]. Studies have emphasized on the pivotal role of pancreatic tumor microenvironment in expediting the initiation and progression of pancreatic cancer, through complex bidirectional signaling pathways between the stroma and tumor cells \[[@bib7]\]. In fact, pancreatic cancer is characterized by extensive fibrosis termed desmoplasia, which is documented in the pathology of PDAC \[[@bib8]\]. High levels of collagen and hyaluronan within the extracellular matrix (ECM) in primary tumors were shown to instigate metastatic disease and poor prognosis among PDAC patients \[[@bib9]\]. Therefore, studying tumor microenvironment players is preponderant on prognosis by affecting the efficacy of different anti-cancer therapies, and targeting tumor microenvironment proteins via new therapeutic strategies \[[@bib10]\].

The CCN family is a complex group of secreted extracellular matrix (ECM)-associated proteins containing six multifunctional members designated CCN1 to CCN6 \[[@bib11],[@bib12]\]. Historically, the CCN acronym was generated from the names of the first three discovered molecules: CYR61 (cysteine-rich protein 61), CTGF (connective tissue growth factor) and NOV (nephroblastoma overexpressed gene) \[[@bib13]\], first described by Bork *et al.* in 1993 \[[@bib11]\]. At the molecular level, these proteins belong to key signaling and regulatory network involved in fundamental biological functions, from wound healing to cell proliferation, differentiation, angiogenesis and tumorigenesis \[[@bib14]\]. Of further interest, functions of both CCN1 (CYR61) and CCN2 appear particularly induced by growth factors, including fibroblast growth factor (FGF) and transforming growth factor-β (TGF-β), leading to enhanced angiogenesis through interactions with angiogenic integrins αvβ3 and α6β1 \[[@bib15],[@bib16]\]. Specifically, CCN1 has been shown to control retinal angiogenesis by targeting VEGF, Src homology 2 domain phosphatase-1 and Notch signaling \[[@bib17]\], and it has a key role in maintaining and enhancing the malignant phenotype in breast cancer \[[@bib18]\].

CCN1, formerly referred to as CYR61, has been also implicated in many human malignancies and according to many reports, its overexpression might serve as a potential prognostic tool. For example, molecular evidence has revealed that CCN1 contributes to glioma progression and overexpression correlates with aggressive behavior \[[@bib19]\]. Additionally, CCN1 overexpression was significantly linked to poor prognosis in muscle-invasive bladder cancer \[[@bib20]\] and lung cancer \[[@bib21]\]. Collectively, these data imply that CCN1 might constitute a viable diagnostic marker and/or a clinical therapeutic target. Yet, patterns of CCN1/CYR61 expression and significance in human PDAC tissue specimens and the interaction between the tumors and their surrounding microenvironment have not been established.

The aim of our pilot study was to understand the expression pattern of *CCN1 (CYR61)* gene in human PDAC tumor tissues and evaluate the correlation between CCN1 staining in stromal cells composed mainly of fibroblasts surrounding the tumor, pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma cells (PDAC) on one hand, and CCN1 staining in normal ductal cells (acinar cells) and normal stromal cells away from the tumor on the other hand, in resected PDAC specimens. Results from our study refer to the role of CCN1 as a potential diagnostic marker and/or therapeutic target in PDAC.

2. Materials and methods {#sec2}
========================

2.1. Patient selection {#sec2.1}
----------------------

Forty-two deceased patients who had undergone pancreaticoduodenectomy at the American University of Beirut Medical Center (AUB-MC), Beirut, Lebanon, between January 2009 and December 2015 were included in this study. All experimental protocols described herein were carried out in accordance with relevant guidelines and regulations, and in agreement with The Code of Ethics of the World Medical Association (Declaration of Helsinki). After Institutional Review Board (IRB) determination of non-human subject research, paraffin-embedded tumor specimens were retrieved and data from medical charts were reviewed. No informed consent was obtained since all patients included are deceased.

2.2. Patient tissue specimens {#sec2.2}
-----------------------------

Archival paraffin blocks were retrieved from the Department of Pathology and Laboratory Medicine of the American University of Beirut Medical Center and paraffin-embedded tissue sections were prepared. These sections were stained with hematoxylin and eosin (H&E) and examined by a specialized pathologist using light microscopy to identify the area of highest histologic tumor grade (Figures [1](#fig1){ref-type="fig"}A, B, C and D). Immunohistochemical staining (IHC) was then performed to estimate levels of CCN1 expression.Figure 1**Immunohistological analysis of a PDAC patient**. Serial sections of pancreatic adenocarcinoma tissues were stained with H&E (A--D) and with CCN1 antibody (E--H). Representative images of normal islet, PanIN2, PanIN3 and invasive tumor (x20) were shown. Normal stromal cells are indicated by an arrow.Figure 1

2.3. Immunohistochemical (IHC) staining {#sec2.3}
---------------------------------------

Unstained paraffin-embedded tissue sections were deparaffinized, and antigen retrieval was performed in a citrate buffer in a steamer at 100 °C for 40 min followed by 30 min incubation at room temperature. Slides were stained with the rabbit polyclonal anti-CCN1 (1/200 dilution) (ab127988; Abcam), according to the Novolink Polymer Kit protocol (Leica biosystems, UK). All slides were counterstained with hematoxylin.

2.4. *IHC Evaluation and scoring* {#sec2.4}
---------------------------------

CCN1 expression was assessed by specialized pathologist in normal ductal cells (acinar cells), normal cells away from the tumor cells, stromal cells adjacent to the tumor, PanIN and ductal cancer cells. CCN1 expression was scored using a semi-quantitative system as follows: 0 (no staining), 1+ (Weak granular cytoplasmic staining), 2+ (Moderate granular cytoplasmic staining) and 3+ (Intense granular cytoplasmic staining) based on the intensity of cells stained. Islet cells were used as an internal control because of their strong CCN1 staining with intensity 3+/3 in all cases.

2.5. Statistical analysis {#sec2.5}
-------------------------

Statistical analysis was performed using the Statistical Package for the Social Sciences statistical package 21.0 software (SPSS, Inc.). Chi- Square test and Fisher\'s exact test were used to study the association of the dependent variable categorized into 4 groups depending on the score of the stain with the specimens clinicopathological characteristics such as PanIN type, cancer stage and grade, in addition to the association between the CCN1 score in PanIN, ductal cancer cells, and adjacent stromal cells. A Mantel--Haenszel test of trend was run to determine whether a linear association existed between PanIN grade and PanIN CCN1 score. A predictive model was built for time-to-death data using Cox regression. P-values less than or equal to 0.05 were considered significant.

3. Results {#sec3}
==========

3.1. *CCN1* (*CYR61*) mRNA expression patterns in human PDAC tissues {#sec3.1}
--------------------------------------------------------------------

In the present study, we aimed at better understanding the expression pattern of *CCN1* (*CYR61*) gene in human PDAC tumor tissues compared to other body tumor tissues. We surveyed a publicly available dataset (Wagner CellLine, 119 samples; data retrieved from [Oncomine.org](http://Oncomine.org){#intref0010}) comprised of human tumor tissues from different organs. Interestingly, analysis revealed that *CCN1* (*CYR61*) gene was highly expressed in PDAC tissues relative to other organ specific tumor tissues in the two probes of the datasets (**Fold change = 2.969; *p = 3.96E-5***) ([Figure 2](#fig2){ref-type="fig"}).Figure 2**Expression levels of*****CCN1*****(*****CYR61*****) mRNA were assessed in the two probes (Reporters 201289_at in (A) and 210764_s\_at in (B)) of an array set comprised of humanpan-tumorsamples (Wagner CellLine Statistics)**. Expression within tumor tissues was presented by log (base 2) median-centered expression of *CCN1* (*CYR61*). Box and whiskers plots indicate median and interquartile range. *p* values were obtained using *t*-tests (Wagner CellLine Statistics, 119 samples; data retrieved from [Oncomine.org](http://Oncomine.org){#intref0015}).Figure 2

3.2. Clinicopathological characteristics of PDAC patients {#sec3.2}
---------------------------------------------------------

A total of 42 PDAC tissues were analyzed by IHC and examined for CCN1 immunoreactivity. Summary of the clinicopathological characteristics, including cancer stage, grade and IHC staining results of the 42 patients are shown in [Table 1](#tbl1){ref-type="table"}. CCN1 expression in islet cells, normal ductal cells (acinar cells) and normal stromal cells was then analyzed and shown in [Table 2](#tbl2){ref-type="table"}.Table 1Characteristics of the patients.Table 1Total NCategoriesnAge (in years)42Mean (±SD)62.2 (±9)Cancer Stage411A31B42A102B24Cancer Grade4017220313Table 2CCN1 expression in islet cells, normal ductal cells (acinar cells) and normal stromal cells.Table 2Clinicopathological ParametersTotal number of patientsCategoriesNumber of patientsCCN1 expression intensity in islets cells42Neg0+0++0+++41N/A1CCN1 expression intensity in normal duct cells (acinar cells)42Neg1+40++0+++0N/A1CCN1 expression in normal stromal cells42Neg1+40++0+++0N/A1[^3]

3.3. CCN1 expression {#sec3.3}
--------------------

CCN1 expression was seen with an intensity of none or 1+ in normal stroma cells and normal ductal cells (acinar cells) of 41/42 of patients, whereas it was identified with an intensity of 3+ in islets (control) of 41/42 of patients ([Figure 1](#fig1){ref-type="fig"}E) ([Table 2](#tbl2){ref-type="table"}). CCN1 expression was seen in the PanIN of 31/42 of patients with an intensity of 1+ in 5/42, 2+ in 19/42 ([Figure 1](#fig1){ref-type="fig"}F) and 3+ in 7/42 ([Figure 1](#fig1){ref-type="fig"}G) ([Table 3](#tbl3){ref-type="table"}A). High CCN1 expression (score 3+) was identified in ductal cancer cells in 18/42 of tumors ([Figure 1](#fig1){ref-type="fig"}H and [Table 3](#tbl3){ref-type="table"}B).Table 3Descriptive table showing the number of patients in each PanIN grade versus the intensity of CCN1 expression in PanIN (A) and number of patients in the different stromal cancer CCN1 scores versus that of ductal CCN1 scores (B).Table 3APanIN GradeTotal**12**3No PanIN ObservedCCN1 expression in PanIN**+**02305**++**1612019**+++**02507**N/A**0001111Total110201142BStromal Cancer CCN1 ScoreTotal+/+++++CCN1 expression in ductal cancer cells+/++24024+++01818Total241842[^4]

Thirty-one of the total 42 specimens were scored for PanIN CCN1 stain. Of the total specimens, 11/42 did not have PanIN. This group was excluded from the following associations as they lack PanIN, and consequently absent CCN1 stain. Higher PanIN grade was associated with statistically significant increase in CCN1 expression. A Mantel-Haenszel test of trend was run to determine whether a linear association exists between the PanIN grade and the PanIN CCN1 score. The Mantel-Haenszel test of trend showed a statistically significant linear association between them, χ2(1) = 19.778, *p* \< .0001, r = 695. Number of patients in each PanIN grade versus the intensity of CCN1 expression in PanIN is shown in [Table 3](#tbl3){ref-type="table"}A.

A stratification of the PanIN CCN1 score has been made according to PanIN type, cancer stage, cancer grade, ductal cancer cells and stromal cancer cells as shown in [Table 4](#tbl4){ref-type="table"}. In studying the association between PanIN CCN1 score and cancer stage, 2/5 of those who had 1 + CCN1 score had a 1B cancer stage, 16/19 from the 2 + CCN1 scores had 2B cancer stage, and finally, 3/6 of those with 3+++ CCN1 score had 2A cancer stage ([Table 4](#tbl4){ref-type="table"}). There was a statistically significant association between PanIN CCN1 scores and cancer stage as assessed by Fisher\'s exact test (*p*-value = 0.006), where advanced cancer stage 2B was associated with higher CCN1 score in PanIN ++. Another significant association was observed between PanIN CNN1 score and cancer grade as shown in [Table 4](#tbl4){ref-type="table"} (*p*-value = 0.031), where high cancer grade of 2 was associated with higher CCN1 score in PanIN of ++.Table 4Association between several clinicopathological factors and expression levels of CCN1 in PanIN.Table 4Clinicopathological ParametersCategoriesCCN1 Score in PanIN*P*-value**++++++TotalNNNN**PanIN Type**1**01011**2**26210**3**312520**Total**519731Cancer Stage**1A**11020.006∗**1B**2013**2A**1236**2B**116219**Total**519630Cancer Grade**1**11350.031∗**2**410115**3**08210**Total**519630CCN1 expression in ductal cancer cells**+/++**512017\<0.0001∗**+++**07714CCN1 expression in stromal cancer cells**+/++**512017\<0.0001∗**+++**07714[^5][^6]

When investigating the relationship between CCN1 score in PanIN to that of ductal and adjacent stromal CCN1 scores, a highly significant association was observed. As shown in [Table 4](#tbl4){ref-type="table"}, all tumor specimens in the 1 + PanIN CCN1 score had a similar ductal and adjacent stromal CCN1 score (1+/2+), and all specimens of 3 + scores had a parallel 3 + score in the ductal and adjacent stromal CCN1 scores (*P*-values ≤ 0.0001).

A Mantel-Haenszel test of trend was run to determine whether a linear association exists between the CCN1 score of the ductal cancer and CCN1 score of the adjacent stroma. The Mantel-Haenszel test of trend showed a statistically significant linear association between them, χ^2^(1) = 39.311, *p* \< .0001, *r* = 979. Higher ductal cancer CCN1 score is associated with a higher adjacent stromal CCN1 score vice-versa ([Figure 3](#fig3){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}B). We also assessed the association between CCN1 expression in PanIN and that of ductal cancer ([Figure 4](#fig4){ref-type="fig"} and [Table 5](#tbl5){ref-type="table"}A), and between CCN1 expression in PanIN and that of stromal cancer ([Figure 5](#fig5){ref-type="fig"} and [Table 5](#tbl5){ref-type="table"}B). The Mantel-Haenszel test of trend showed no statistically significant linear association between them, χ^2^(1) = 2.095, *p* = 0.148, r = 0.226 (same results with the ductal and stromal as they have similar counts).Figure 3Scatterplot showing the linear trend between stromal cancer CCN1 score and ductal cancer CCN1 score.Figure 3Figure 4Scatterplot showing the relation between CCN1 expression in PanIN and that of ductal cancer.Figure 4Table 5Descriptive table showing the number of patients with different intensities of CCN1 expression in PanIN versus that in ductal cancer cells **(A)** and that of stromal cancer cells **(B)**.Table 5CCN1 Expression in PanINTotal++++++N/AACCN1 expression in ductal cancer cells**+/++**5120724**+++**077418**Total**51971142BCCN1 expression in stromal cancer cells**+/++**5120724**+++**077418**Total**51971142Figure 5Scatterplot showing the relation between CCN1 expression in PanIN and that of stromal cancer.Figure 5

3.4. Survival analysis {#sec3.4}
----------------------

We found no significant difference in median overall survival between cases with high CCN1 expression (+++) in ductal and stromal cancer cells compared to cases with low to moderate CCN1 staining (+ or ++) ([Figure 6](#fig6){ref-type="fig"}). In multivariable model adjusting for age, cancer stage and cancer grade, CCN1 staining was not an independent factor associated with survival in this cohort (data not shown).Figure 6Kaplan-Meier survival curves for patients with CCN1 staining in ductal cancer cells (+++) compared to low to moderate staining (+/++).Figure 6

4. Discussion {#sec4}
=============

To the best of our knowledge, this is the first pilot study to investigate the relationship comparing CCN1 expression in PanIN to CCN1 in ductal tumor cells and the adjacent stroma in resected PDAC specimens. Although this pilot study is limited by a small sample size, we have demonstrated that CCN1 moderate (2+) and overexpression (3+) is higher in PanIN grade 3 in this cohort of patients. Almost two-thirds of PanIN CCN1 2+ and 3+ were found in PanIN grade 3 ([Table 4](#tbl4){ref-type="table"}). A statistically significant linear correlation was seen between CCN1 score of the ductal cancer and CCN1 score of the adjacent stroma. Also, significant association was found between CCN1 expression in PanIN on one hand, and CCN1 expression in ductal tumor cells and adjacent stromal cells on the other hand, where all tumor specimens in the 1 + PanIN CCN1 score had a similar ductal and adjacent stromal CCN1 score (1+/2+), and all specimens of 3 + scores had a parallel 3 + score in the ductal and adjacent stromal CCN1 scores (*P*-values ≤ 0.0001). Yet, in this small cohort, CCN1 expression in ductal and stromal tumor cells was not found to be associated with median overall survival of patients.

Review of literature on the role of CCN1 in different other cancers, it was also found to be expressed at elevated levels in advanced breast cancers where it is thought to promote invasiveness \[[@bib18], [@bib22]\]. In laryngeal squamous cell cancer, overexpression of CCN1 was shown to induce epithelial-mesenchymal transition (EMT), therefore leading to invasion, metastasis and poor prognosis \[[@bib23]\]. Furthermore, CCN members (including CCN1) were highly dysregulated in colorectal cancer, and appear to be involved in initiation, development, and progression of the disease \[[@bib22]\]. CCN1 silencing was also found to potentially blunt tumor vasculature and slow growth of osteosarcoma cells \[[@bib24]\], thereby limiting the number of corresponding lung metastases.

In a study by Sano *et al.*, authors employed gene expression profiling to identify target molecules of the WNT/β-catenin signaling pathway in pancreatic cancer cells *in vitro* \[[@bib25]\]. Results from this study revealed that WNT/β-catenin signaling pathway enhances pancreatic cancer development and malignancy via up-regulation of CYR61. Another study by Haque *et al.* demonstrated the involvement of Cyr61/CCN1 in pancreatic carcinogenesis via promoting EMT and stemness \[[@bib26]\]. Besides, the Sonic Hedgehog (SHh) and Notch 1 pathways have been shown to serve as critical regulators in pancreatic carcinogenesis through CCN1-dependent cell migration and tumorigenicity \[[@bib27]\], and through promoting endothelial cell migration and aberrant neovascularization \[[@bib28]\].

The associations we have demonstrated between CCN1 expression in PanIN and tumor-adjacent stroma suggest that CCN1 might play an important role in the interaction between the pancreatic tumors and their surrounding stromal microenvironment in additional to their microscopic precursors, i.e. the PanINs. Studies have shown that components of the PDAC microenvironment, including the ECM, matrix metalloproteinase (MMP), growth factors, and TGFβ, contribute to desmoplasia and are associated with poor patient prognosis \[[@bib8]\]. Reports from basic research studies are consistent with this where Haque *et al.* \[[@bib26]\] showed that CCN1 mRNA and protein expression was elevated in pancreatic cell lines and that silencing CCN1 blocked cell migration, EMT and tumor formation in mice. CCN1 was also found to activate the sonic hedgehog (SHh) and the notch pathways through autocrine-paracrine circuits to promote endothelial cell migration and tumor angiogenesis \[[@bib27]\]. SHh is known to affect tumor growth by promoting desmoplasia, a network of fibrotic tissue facilitating tumor invasion \[[@bib28], [@bib29]\]. Additional studies on cell lines have suggested that CCN1 overexpression promotes resistance to gemcitabine chemotherapy through the regulation of cancer cell-secreted connective tissue growth factor (CTGF), a regulator of desmoplasia, and deoxycytidine kinase (dCK), an enzyme that enhances gemcitabine sensitivity and efficacy in cancer cells \[[@bib30], [@bib31]\].

Further mechanistic studies are on-going to elucidate the role of CCN1 in the development and progression of pancreatic adenocarcinoma with small-molecule inhibitors of the hedgehog pathway, a potential therapeutic strategy in clinical development \[[@bib32]\].

5. Limitations {#sec5}
==============

We believe that our pilot study has some limitations. First, although this is the first translational research paper to evaluate the expression patterns of *CCN1* (*CYR61*) in human PDAC tumor tissues and surrounding microenvironment, the sample size is relatively small and we acknowledge that we have some missing data in the medical records of patients, which might have contributed to the absence of significant prognostic correlation between CCN1 expression and patients\' survival. Henceforth, the results obtained require conducting subsequent studies on a larger cohort and avoiding missing data. In accordance, we believe that more data and follow up is required to assess the correlation of CCN1 expression with clinical outcomes. Second, our study focuses on deciphering the correlation between CCN1 expression in tumor cells and their microenvironment, rather than on the prognostic value of CCN1. In this milieu, it has been postulated that the pancreatic tumor microenvironment plays a pivotal role in expediting the initiation and progression of pancreatic cancer. Therefore, our aim was to assess the patterns of CCN1/CYR61 expression and significance in human PDAC tissue specimens and the interaction between the tumors and their surrounding microenvironment. Results from our study reveal that CCN1 might constitute a viable diagnostic marker and/or a clinical therapeutic target for PDAC. Third, samples were collected retrospectively over the period of 6 years between January 2009 and December 2015, which attests to the restricted sample size obtained. Fourth, our small sample size and retrospective collection of data with some missing information might explain the possible lack of significant association between increased ductal tumor CCN1 expression and poor outcome. Lastly, we acknowledge that islets of Langerhan\'s immunoreaction might exhibit false-positive staining.

6. Conclusions {#sec6}
==============

In a sample of resected adenocarcinoma specimens, we have demonstrated that CCN1 moderate and overexpression in PanIN is higher in PanIN grade 3. Significant association was seen between PanIN CCN1 expression, ductal tumor cell CCN1 expression and CCN1 expression in adjacent stromal cells. These results reinforce the potential role of CCN1 as a diagnostic marker and/or therapeutic target in PDAC. Although increased ductal tumor CCN1 expression was not associated with poor outcome in our small cohort, studies in our lab targeting the CCN1-mediated tumor-stromal interaction in pancreatic cancer are still ongoing. Further studies could be also employed to correlate between CCN1 expression and other important molecular factors in pancreatic tumor like Wnt signaling or Ki67.
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